ÂÜÀòÂÒÂ×

Allen Barbieri has a extensive work experience in various industries. Currently, they are the Chairman/CEO of Kuleon Bioscience, a drug discovery company. Allen has led the development of new patented drugs for the treatment of schizophrenia, obesity, addiction, and chronic depression. Previously, they served as Vice Chairman and Board Member at Biomerica, Inc., where they led board meetings and managed strategic projects and partnerships. Allen was also a Board Member at CareTrust REIT, a healthcare real estate investment trust, where they chaired the Corporate Governance and Nominating Committee and participated in the Audit and Compensation Committees. Prior to that, they served as Chairman/CEO at Biosynthetic Technologies, a technology company that developed and commercialized bio-based industrial oils. Allen successfully raised $60 million in VC funding, filed numerous patents, and oversaw the sale of the company to a large international chemicals PE fund. Additionally, they were the CEO of Lancer Orthodontics, where they managed sales, manufacturing, distributor relationships, and strategy. Allen also held leadership positions at BUY.COM, Pacific National Bank, Alta Residential Mortgage Trust - REIT, Capital Bancorp, and First Federal Bank, where they demonstrated proficiency in finance, operations management, and strategic planning.

Allen Barbieri has an MBA degree in Finance & International Economics from the MIT Sloan School of Management. Prior to that, they completed their undergraduate studies at Brigham Young University, earning a B/S degree in Business Finance.